Literature DB >> 22617774

HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells.

Chunhong Wang1, Guangru Fei, Zhongmin Liu, Qinchuan Li, Zengguang Xu, Tao Ren.   

Abstract

High-mobility group box 1 (HMGB1) has been implicated in a variety of biologically important processes, including transcription, DNA repair, differentiation, development, and extracellular signaling. However, the potential role of HMGB1 in tumor biology still remains intractable. Our previous study showed that TLR9 response to CpG oligonucleotide (ODN) in 95D human lung cancer cells could enhance their growth and invasive potential in vitro and in vivo. Here we found that CpG ODN stimulation to 95D cells induced the secretion of HMGB1 in a dose dependent manner. We further showed that blockade of extracellular HMGB1 using A box peptide and ethyl pyruvate significantly abrogated the CpG ODN enhanced progression of 95D cells. Interestingly, we found that HMGB1 alone or acted synergistic with CpG ODN could enhance the progression of 95D cells. Notably, we revealed that RAGE and TLR4 were critical for HMGB1 to exert the synergistic function. We observed a MyD88-dependent upregulation of matrix metalloproteinase (MMP) 2, MMP9 and cyclin-dependent kinase (CDK) 2 in 95D cells in response to HMGB1. These findings might further our understanding of TLR9 signaling in tumor biology and be helpful for developing HMGB1-based strategy against lung cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617774     DOI: 10.4161/cbt.20555

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  19 in total

1.  Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis.

Authors:  Jin-Cheng Zeng; Wen-Yu Xiang; Dong-Zi Lin; Jun-Ai Zhang; Gan-Bin Liu; Bin Kong; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Lai-Long Yi; Ji-Xin Zhong; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

3.  MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma.

Authors:  Peng Xiao; Wen-Liang Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  D-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in mice.

Authors:  Tomasz Cichoń; Ryszard Smolarczyk; Sybilla Matuszczak; Magdalena Barczyk; Magdalena Jarosz; Stanisław Szala
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-02-02       Impact factor: 4.291

5.  The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy.

Authors:  Zengguang Xu; Fengying Wu; Chunhong Wang; Xiyu Liu; Baoli Kang; Shan Shan; Xia Gu; Kailing Wang; Tao Ren
Journal:  Cancer Cell Int       Date:  2014-08-12       Impact factor: 5.722

6.  MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer.

Authors:  Qinchuan Li; Xiaoman Li; Zhongliang Guo; Feng Xu; Jingyan Xia; Zhongmin Liu; Tao Ren
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

Review 7.  Oxidized extracellular DNA as a stress signal in human cells.

Authors:  Aleksei V Ermakov; Marina S Konkova; Svetlana V Kostyuk; Vera L Izevskaya; Ancha Baranova; Natalya N Veiko
Journal:  Oxid Med Cell Longev       Date:  2013-03-06       Impact factor: 6.543

8.  Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway.

Authors:  Zhichao Huang; Zhaohui Zhong; Lei Zhang; Xinjun Wang; Ran Xu; Liang Zhu; Zijian Wang; Shanbiao Hu; Xiaokun Zhao
Journal:  Sci Rep       Date:  2015-08-04       Impact factor: 4.379

Review 9.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

10.  Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer.

Authors:  Xiaohong Zhang; Hongmin Wang; Jing Wang
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.